GHRH (Growth Hormone Releasing Hormone)
Also known as: Growth Hormone Releasing Hormone
GHRH is an endogenous hypothalamic peptide that stimulates the pituitary gland to release growth hormone. CJC-1295 and Sermorelin are synthetic GHRH analogues used in research.
Overview
GHRH is a 44-amino-acid peptide secreted by the hypothalamus that acts on specific receptors in the anterior pituitary, triggering pulsatile growth hormone (GH) release. Endogenous GHRH has a short half-life of approximately 6–8 minutes due to rapid enzymatic degradation by DPP-IV enzymes. Synthetic GHRH analogues such as Sermorelin (a 29-AA fragment) and CJC-1295 (a modified 30-AA analogue) are engineered to resist this degradation and have extended half-lives ranging from 30 minutes (Sermorelin) to 6–8 days (CJC-1295 with DAC modification). These analogues stimulate GH release through the same physiological pathway as endogenous GHRH, preserving the natural pulsatile pattern of GH secretion.
Related Peptide Profiles
Frequently asked questions
What is the difference between GHRH and GHRP?+
GHRH stimulates GH release via the GHRH receptor. GHRPs (Growth Hormone Releasing Peptides) stimulate GH via the ghrelin receptor — a different pathway. Combining both types targets two independent stimulation pathways.
How does CJC-1295 differ from natural GHRH?+
CJC-1295 has amino acid substitutions and (in the DAC form) a drug affinity complex that binds albumin in the bloodstream, extending its half-life from minutes to 6–8 days.
Does GHRH directly increase IGF-1?+
GHRH stimulates GH release, and GH in turn causes the liver to produce IGF-1. So GHRH elevates IGF-1 indirectly, via the GH/IGF-1 axis.